Welcome to our dedicated page for BIODESIX news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on BIODESIX stock.
Biodesix, Inc. reports developments as a diagnostics solutions company focused on lung disease testing and biopharma development services. Its updates center on Diagnostic Tests such as Nodify Lung® Nodule Risk Assessment, Nodify CDT® and IQLung® Cancer Treatment Guidance, along with blood- and tissue-based testing, proteomic and genomic approaches, and development work for life sciences partners.
Recurring news also covers quarterly results, revenue guidance, test-volume trends, clinical validation studies, real-world evidence presentations at medical meetings, and the company’s efforts to expand evidence for lung nodule management and oncology testing applications.
Biodesix Inc. (BDSX) has partnered with Spesana to enhance molecular diagnostics in lung cancer management across the U.S. This collaboration focuses on streamlining clinical workflows using Spesana's cloud-based platform. It aims to improve patient outcomes by automating processes like referral management and clinical trial management.
The platform will integrate Biodesix’s blood-based Nodify Lung® tests, which assess nodule risk in lung disease. The goal is to simplify the complex diagnostic journey for providers and ensure patients receive timely and precision treatments.
Biodesix (NASDAQ: BDSX) has announced interim results from the INSIGHT study, which involved approximately 2,000 NSCLC patients. The findings indicate that patients classified as HIC-Hot by the VeriStrat test lived 2-3 times longer than those classified as HIC-Cold. This suggests that the VeriStrat test can effectively guide immunotherapy treatment, improving survival rates. The study emphasizes the significance of immune classification in optimizing treatment strategies for advanced non-small cell lung cancer.
Biodesix, Inc. (BDSX) reported a 51% increase in lung diagnostic revenue to $4.5 million for Q3 2021, driven by Nodify nodule management tests and a growing sales force. Total revenue reached $6.5 million, with services revenue up 133% to $1.5 million. However, COVID-19 testing revenue fell 91% to $0.5 million. The gross margin improved to 58%, while operating expenses increased 46% to $16.9 million, resulting in a net loss of $11.5 million. The company launched a 72-hour liquid NGS test ahead of schedule and anticipates continued growth into 2022.
Biodesix, Inc. (NASDAQ: BDSX) announced its collaboration with Genentech to present three posters at the 36th Annual Society for Immunotherapy of Cancer (SITC) from Nov. 10-14, 2021. This research focuses on diagnostic tests for non-small cell lung cancer (NSCLC) patients undergoing immune checkpoint inhibitor therapy. CEO Scott Hutton highlighted the importance of quick, actionable test results for patient care. Key presentations include findings on the Primary Immune Response (PIR) test and Anti-PD-L1 Response Test (ART), emphasizing their potential in predicting treatment efficacy.
Biodesix, Inc. (NASDAQ: BDSX) announced that CEO Scott Hutton will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on November 18, 2021, at 4:30 PM ET. The event will be webcasts live and available for replay on the Company's website. Biodesix specializes in data-driven diagnostic solutions for lung disease, offering innovative non-invasive tests and leveraging AI for enhanced diagnostics. For more information about Biodesix, visit biodesix.com.
Biodesix, Inc. (BDSX) will announce its third quarter financial results for the period ending September 30, 2021, before market open on November 15, 2021. The company will host a conference call at 9:00 a.m. Eastern Time to discuss these results and provide a business update. Biodesix specializes in data-driven diagnostic solutions for lung disease, offering non-invasive tests like Nodify Lung® and Biodesix Lung Reflex® to support patient management. These initiatives potentially influence treatment timelines and decision-making processes in lung disease care.
Biodesix (NASDAQ: BDSX) announced new findings from its ORACLE study presented at the 2021 CHEST virtual conference, showcasing its Nodify XL2 blood test's ability to reduce unnecessary invasive procedures by up to 67% for patients with benign lung nodules. The study, which evaluated 331 patients, demonstrated significant reductions in biopsies and surgeries, enhancing patient management and overall peace of mind. The results further validate previous data from the PANOPTIC trial, indicating potential improvements in patient care and clinical outcomes.
Biodesix, Inc. (NASDAQ: BDSX) reported significant findings presented at the IASLC World Conference on Lung Cancer, emphasizing the role of genomic and proteomic testing in improving treatment outcomes for lung cancer patients.
Key studies included a blood-based proteomic test predicting survival in non-small cell lung cancer patients undergoing immunotherapy, and the rapid turnaround of a KRAS test that allows for expedited treatment decisions. CEO Scott Hutton highlighted the goal of enhancing patient outcomes while reducing healthcare costs.
Biodesix, a data-driven diagnostic solutions company, will present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 9, 2021. CEO Scott Hutton is scheduled to participate in a fireside chat at 4:15 PM ET.
The event will be available for live webcast and replay on the company's website. Biodesix specializes in lung disease diagnostics, with a portfolio that includes non-invasive tests and advanced AI integration, supporting rapid treatment decisions for lung cancer patients.
Summary not available.